Floblu14, First of all thank you for helping me get my email problem fixed. The copy and paste solution was a major "duh" on my part but the pop up problem was real and no other solutions suggested by other board members worked. You think the ART-1 investors are not happy because of study outcome? If the company were not happy I doubt we would be seeing an 800 patient phase III study and the financial resources that entails. So, in reading the paper posted by Dew, there was inbetween the lines oblique reference to antithrombin as another anticoagulant in a 1999 paper that compared six anticoagulants. If I have time I will try to get this and review for the board. Also Dr. Cox has always mentioned ATIII has antiinflamatory effects also and anyone knowlegeble who can contrast this to the protein C mediated antiinflammatory effects of the ART product might give us a window into similarities and differences. T 1/2 of thrombomodulin seems longish this could be good or bad, does anyone know how this compares to ATIII (always good to just shut off a drip and have a short T 1/2 if for so reason one needs to. I agree the Art results don't seem that impressive. Those who have treated DIC with heparin know it is worthless. Is the control arm in the phase III ART study heparin or nothing. (Would that there were a third arm of AT III!) Especially with such a large study powered for survival. The ART study looked like it took about 5 years! And multiple sites were part of it. Wonder if our strategy is to have smaller and faster phase III study that could be stopped by data safety and monitoring board if results were great. Regards, to all Let me know if anyone is interested and I can persue trying to get selected papers from the bibliography for the board unless Dew or Flo already have them in their files. Regards to all, bp
Market Data 
Markets 
AI
